Abstract
Background: Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence. We assessed the efficacy of Temozolomide as second-line therapy following failure of PCV chemotherapy in patients with recurrent/progressive gliomas.
Patients and methods: Between September 1994 and November 2000, 32 patients with high-grade gliomas at second recurrence/progression received Temozolomide as salvage therapy and results were received retrospectively.
Results: Of 32 assessable patients 7 had clinical improvement; there were no imaging responses. Median survival of the cohort was 4 months, with 28% alive at 6 months. Age, performance status, histology and previous response to PCV chemotherapy did not predict for clinical response to Temozolomide.
Conclusion: In the small cohort of patients with recurrent malignant glioma who failed PCV chemotherapy Temozolomide demonstrated limited activity as second-line treatment although this remains within the confidence intervals of response seen in patients with glioblastoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Thomas DGT, Brada M, Stenning SP, on behalf of the MRC Brain Tumour Working Party: A randomised trial of Procarbazine, Lomustine and Vincristine in the adjuvant treatment of high grade astrocytoma-a Medical Research Council Trial. J Clin Oncol 19: 509-518, 2001
Rajan B, Ross G, Lim CC, Ashley S, Goode D, Traish D: Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer 12(15): 1809-1815, 1994
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8): 2572, 1999
Newlands E, Blackridge G, Slack J: Phase I trial of temozolomide (CCRG 81045: M&B: NSC 362856). Br J Cancer 65(2): 287-291, 1992
Brada M, Judson I, Beale P: A phase I dose escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81(6): 1022-1030, 1999
Bower M, Newlands E, Bleehan N, Brada M, Begent R, Calvert H: Multicentre CRC phase II trial of temozolmide in high grade glioma. Cancer Chemother Pharmacol 40: 484-488, 1997
Brada M, Hoang-Xuan K, Rampling R: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12(2): 259-266, 2001
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5): 588-593, 2000
Yung W, Prados M, Yaya-Tur R, Rosenfeld S, Brada M, Friedman H: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17: 2762, 1999
Osoba D, Brada M, Yung WK, Prados MD: Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 36(14): 1788-1795, 2000
Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7): 1277-1280, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Trent, S., Kong, A., Short, S. et al. Temozolomide as Second-line Chemotherapy for Relapsed Gliomas. J Neurooncol 57, 247–251 (2002). https://doi.org/10.1023/A:1015788814667
Issue Date:
DOI: https://doi.org/10.1023/A:1015788814667